■哮喘是一种复杂的疾病,以气道炎症为特征,涉及表观遗传变化,遗传和环境因素共同作用。MicroRNAs作为候选生物标志物在免疫和炎性疾病的诊断和治疗中作为靶分子而脱颖而出。这项研究的目的是鉴定被认为在过敏性哮喘的发病机理中有效的miRNA,并揭示与该疾病相关的候选生物标志物。
■50名患者,年龄在18-80岁之间,被诊断为过敏性哮喘的患者和18名健康志愿者被纳入研究.从志愿者身上采集两毫升总血液后,进行RNA分离和cDNA合成。对于miRNA谱筛选,通过使用miScriptmiRNAPCR阵列的实时PCR方法进行表达分析。GeneGlobe数据分析中心用于评估失调的miRNA。
■在过敏性哮喘组中,9例(18%)患者为男性,41例(82%)为女性。在对照组中,男性7例(38.89%),女性11例(61.1%)(P:0.073)。作为研究的结果,miR-142-5p的表达水平,miR-376c-3p和miR-22-3p下调,而miR-27b-3p,miR-26b-5p,miR-15b-5p和miR-29c-3p被检测为上调。
■我们的研究结果表明miR142-5p,miR376c-3p和miR22-3p通过涉及p53信号通路的机制抑制TGF-β表达促进泛素介导的蛋白水解。失调的miRNA可用作哮喘的诊断和预后生物标志物。
Asthma is a complex disease characterized by inflammation of the airways, involving epigenetic changes, in which genetic and environmental factors act together. MicroRNAs as candidate biomarkers stand out as target molecules in the diagnosis and treatment of immunological and inflammatory diseases. Our aim of this study is to identify miRNAs that are thought to be effective in the pathogenesis of allergic asthma and to reveal candidate biomarkers associated with the disease.
Fifty patients, aged between 18-80 years, who were diagnosed with allergic asthma and 18 healthy volunteers were included in the study. After the collection 2 mL of total blood from volunteers, RNA isolation and cDNA synthesis were performed. For miRNA profile screening, expression analysis was performed by real-time PCR method using miScript miRNA PCR Array. GeneGlobe Data Analysis Center was used to evaluate dysregulated miRNAs.
In the allergic asthma group, 9 (18%) of the patients were male and 41 (82%) of them were female. In the control group, 7 (38.89%) were male and 11 (61.1%) were female (P:0.073). As a result of the research, the expression levels of miR-142-5p, miR-376c-3p and miR-22-3p were down-regulated, while miR-27b-3p, miR-26b-5p, miR-15b-5p and miR-29c-3p detected as up-regulated.
The results of our study suggest that miR142-5p, miR376c-3p and miR22-3p promote Ubiquitin-mediated proteolysis by inhibiting TGF-β expression through a mechanism involving the p53 signaling pathway. The deregulated miRNAs may be used as a diagnostic and prognostic biomarker in asthma.